$ 2.01
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100,...
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. Specifically, the stock is undervalued on EV/EBITDA.
Target Price
The average target price of INAB is 57 and suggests 2710% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
